The ASH meeting is held annually to promote the development, advancement and exchange of scientific and clinical information regarding all aspects of research, diagnosis and treatment of hypertension and related cardiovascular diseases. More than 4,000 physicians, scientists, pharmacists, nurses and other health care professionals from the U.S. and foreign countries attend this meeting which is certified by the Accreditation Council for Continuing Medical Education to provide ongoing medical education.

There were more than fifty oral and poster sessions presented at the ASH meeting regarding the anatomical structure and compliance of arteries. Of these, eight were presented by investigators who used HDI/PulseWave™ and CVProfilor^® cardiovascular profiling technology in their clinical research. Dr. L.M. Resnick (Hypertension Center, N.Y. Presbyterian-Cornell Medical Center, N.Y.) and colleagues reported that arterial elasticity improves with the administration of some, but not all, antihypertensive drugs, and that such improvement appears to offer greater clinical benefit to patients. Researchers from the University of Minnesota Medical School and the St. Paul Heart Clinic demonstrated that nitric oxide released from the endothelial lining of thin-walled small arteries modifies vascular tone or compliance. In a second study, these same researchers showed that despite a blood pressure rise, large artery size and elasticity were unaffected by the intravenous infusion of a nitric oxide synthase inhibitor. Using the HDI/PulseWave™ CR-2000 Research System, Drs. Lane and Prisant (Cardiology Section, Medical College of Georgia) tested 59 healthy human subjects on two occasions separated by about 50 days and showed that the short-term repeatability of the parameters generated by the System are stable. Dr. D.A. Duprez (University Hospital in Gent, Belgium) and colleagues studied well-trained male athletes and discovered that athletic training appears to enhance large artery elasticity which has a favorable clinical effect on cardiac flow. Research conducted by Dr. A. Zimmermann and associates (Brookdale University Hospital & Medical Center, and S.U.N.Y. Health Science Center, N.Y.) suggests that the loss of small artery elasticity may be the earliest detectable change in arteries, manifesting itself in people in their 20s and 30s, even before the development of elevated blood pressure. It was demonstrated by Dr. N. Winer and researchers at the University of Missouri School of Medicine (Kansas City) that healthy young women have reduced small artery elasticity compared to age-matched men despite having lower blood pressure and more favorable lipid, insulin and homocysteine levels. Dr. Grey and other clinical researchers at the University of Minnesota Department of Cardiology measured large and small artery elasticity in more than 400 human subjects recruited for various clinical studies. They determined (via self-administered questionnaire) that, during a 1 to 7 year follow-up time period, 168 subjects (42%) experienced new or second cardiovascular events which were associated with having reduced small artery elasticity. While large artery elasticity was associated with age in these subjects, it did not predict outcome as did small artery compliance.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not predictions of actual future results. Actual results could differ materially from those anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 1999 Annual Report on Form 10-KSB under the caption "Risk Factors," as well as others not now anticipated. These risks and uncertainties include, without limitation, the Company's ability to receive regulatory approval for its CVProfilor^® DO-2020 System; the availability of third-party reimbursements; market acceptance of the Company's products; the ability to operate and maintain the Central Data Management Facility ("CDMF") on a commercial scale; regulatory restrictions pertaining to data privacy issues in utilizing the CDMF; the ability of third parties to manufacture the Company's products on a commercial scale and in compliance with regulatory requirements; the availability of integral components for the Company's products; the Company's ability to develop distribution channels; increased competition; changes in government regulation; health care reform; exposure to potential product liability; and the Company's ability to protect its proprietary technology.

Hypertension Diagnostics™, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President